Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

Neodolpasse combines an NSAID and a central muscle relaxant to address conditions involving pain, inflammation, and muscle spasm.

• Acute postoperative pain: provides rapid analgesia and reduces inflammatory response, facilitating early mobilization after surgery.
• Musculoskeletal inflammation: decreases swelling and pain in conditions such as sprains, strains, and arthritic flare‑ups, improving joint function.
• Muscle spasm associated with orthopedic injuries: relaxes skeletal muscle tone and alleviates discomfort, supporting physiotherapy and rehabilitation.

• Diclofenac sodium inhibits cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, lowering prostaglandin synthesis and thereby reducing inflammation and pain. Orphenadrine citrate acts as an anticholinergic agent that blocks central muscarinic receptors and exerts a direct central muscle‑relaxing effect, decreasing skeletal muscle tone and pain perception.

Neodolpasse may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea: mild gastrointestinal upset occurring in some patients.
• Headache: transient headache reported after infusion.
• Dizziness: occasional light‑headedness during or after administration.
• Injection site pain: local discomfort at the IV site.
• Mild hypotension: transient drop in blood pressure.
• Transient liver enzyme elevation: mild, reversible changes.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Gastrointestinal bleeding: risk of ulceration or hemorrhage, especially with concurrent NSAIDs.
• Hepatic injury: potential for serious liver dysfunction.
• Renal impairment: acute kidney injury in susceptible individuals.
• Cardiovascular events: increased risk of myocardial infarction or stroke.
• Neutropenia: rare reduction in white blood cell count.

Neodolpasse should be used with careful clinical assessment and monitoring.

• Renal function: assess baseline renal status and monitor during therapy.
• Hepatic function: use with caution in patients with liver disease.
• Cardiovascular risk: avoid in patients with uncontrolled hypertension or heart failure.
• Bleeding risk: monitor for signs of gastrointestinal bleeding, especially with concurrent anticoagulants.
• Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Neodolpasse may interact with several drug classes; clinicians should review patient medication profiles.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased bleeding risk.
• Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity.
• Lithium: diclofenac may raise lithium serum levels.
• Methotrexate: reduced clearance leading to toxicity.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may diminish renal function.
• Diuretics: heightened risk of renal impairment.
• Corticosteroids: increased likelihood of gastrointestinal ulceration.